Research article

Prevalence of NPHS2 gene R229Q polymorphism in Bangladeshi children with nephrotic syndrome

Sharmin Sultana Jyoti\textsuperscript{a}, Farhana Islam\textsuperscript{a}, Ishrat Islam Shrabonee\textsuperscript{b}, Taposhi Nahid Sultana\textsuperscript{a}, Nusrat Islam Chaitya\textsuperscript{b}, Noor Ahmed Nahida\textsuperscript{a}, Md Reazul Islama, Md Saiful Islama, Mohd Nazmul Hasan Apua\textsuperscript{a,}\textsuperscript{*}

\textsuperscript{a} Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka, 1000, Bangladesh
\textsuperscript{b} Department of Pediatric, Mymensingh Medical College Hospital, Mymensingh, 2200, Bangladesh

ARTICLE INFO

Keywords: Clinical genetics Human genetics Genetic disorders Pediatrics Steroid resistant nephrotic syndrome NPHS2 R229Q polymorphism PCR-RFLP Bangladesh

ABSTRACT

Background: Limited and contradictory pharmacogenetic studies of NPHS2 gene R229Q polymorphism in nephrotic syndrome (NS) children of different ethnicities steered us to investigate the genotype frequency and associated risk of this polymorphism in Bangladeshi NS children.

Methods: A prospective case-control study was conducted which comprised a total of 142 children having nephrotic syndrome (NS), divided into 2 groups: case group consisted of 40 children with steroid-resistant nephrotic syndrome (SRNS), and control group involved 102 children with steroid-sensitive nephrotic syndrome (SSNS). Both were genotyped by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method for R229Q polymorphism.

Results: The results indicate the presence of R229Q polymorphism in 27.50% of SRNS and 12.75% of SSNS children. SRNS children possess 2.94-fold greater risk ($p = 0.025$) of carrying Arg/Gln genotype compared to SSNS children. Moreover, R229Q variant in SRNS children was observed as in a compound heterozygous form with p.Ala297Val located in exon 8. Age of onset (4–6 years) presents as a significant contributing factor (adjusted OR = 1.06; 95% CI = 1.023–1.094; $p = 0.001$) for SRNS susceptibility in Bangladeshi children. Contrarily, though the incidence of SRNS was higher in male children than female (80% vs 20%), gender remains to be a neutral factor ($p = 0.257$) in relation to SRNS susceptibility.

Conclusion: Compound heterozygosity of NPHS2 p.R229Q gene variant with p.Ala297Val may cause pathogenic SRNS in Bangladeshi children. Large scale studies are warranted to establish the genotype-phenotype correlation. It is recommended to screen for p.R229Q first and, if positive, for p.Ala297Val in Bangladeshi SRNS children.

1. Introduction

Nephrotic syndrome (NS) is a nonspecific renal disorder which is characterized by heavy proteinuria, edema and hypoalbuminemia \cite{1, 2} accompanied by several pathomorphologic entities with glomerular lesions \cite{3}. All these characteristic features primarily develop from the alteration of permselectivity barrier of the glomerular capillary wall and as a result the capillary wall loses its ability to restrict the loss of protein to <100 mg/m² body surface per day. In children, the treatment is strongly based on corticosteroid therapy \cite{4}. Depending on the response to steroid therapy, NS is classified into steroid sensitive nephrotic syndrome (SSNS) and steroid resistant nephrotic syndrome (SRNS) \cite{2, 3}.

Most of the patients respond to steroid therapy; however, approximately 10–20% of the patients fail to respond to steroid therapy \cite{2, 5, 6}.

Podocin is a membrane protein belonging to the stomatin family of lipid-raft associated protein and exclusively expressed in the podocytes, the key component of glomerular basement membrane \cite{7}. It is an integral protein consisting of 383 amino acids having a unique topology (a single short hairpin-like transmembrane domain and cytosolic N- and C-terminal domains) \cite{8}. Podocin oligomerizes and these podocin clusters along with other podocyte proteins such as nephrin and CD2AP in lipid rafts ensure the proper functioning of filtration slits \cite{9}.

Mutations in NPHS2 gene, encoding podocin result in a reduction or absence of functional protein and thus impair the formation of normal slit diaphragms \cite{3, 10, 11, 12}. This leads to SRNS before 6 years of age and

* Corresponding author.
E-mail addresses: nazmul.apu@du.ac.bd, nazmulapu43@gmail.com (M.N.H. Apu).

https://doi.org/10.1016/j.heliyon.2020.e05317
Received 14 April 2020; Received in revised form 12 September 2020; Accepted 16 October 2020
2405-8440/© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
reach end stage renal disease (ESRD) during their first decade of life [3]. Several studies have investigated many potential genetic variants of NPHS2 gene. The variant p.R229Q (c.686G > A; rs61747728), a non-synonymous variant in exon 5, is affirmed to be one of the most important predictive factors in the pathogenesis of SRNS [13, 14]. Evidence confirmed that the R229Q allele is a disease-causing, rather than a benign polymorphism [15]. However, the susceptibility to R229Q polymorphism varies among different ethnic groups. The susceptibility of NS in Asian children is 9–16 per 100,000 [16,17], which is 2–7 per 100,000 children in USA [18] and 2–4 new cases per 100,000 children in UK [17, 19]. The rate of such incidence in Bangladesh is not reported yet. Therefore, we aimed to investigate the genotypic distribution of R229Q variant of NPHS2 gene and thus finding its associated risk with SRNS in Bangladeshi children.

2. Materials and methods

2.1. Subject selection

The current study was conducted on 40 SRNS (cases) and 102 SSNS (controls) children. Patients who achieved complete remission with steroid therapy were classified as having SRNS. And those who failed to achieve remission following 4-week of 60 mg/m²/day prednisolone treatment were identified as having SRNS. So, volunteers of SRNS and SSNS were selected according to expert physicians’ diagnosis of the type of NS after treating with prednisolone. The study was carried out by recruiting patients from Bangladesh Sheikh Mujib Medical University (BSMMU), Dhaka and Mymensingh Medical College Hospital (MMCH), Mymensingh between the period of January 2018 and September 2019. The study protocol was approved by the ethical committees of the respective hospitals and the study was conducted in accordance with the declaration Helsinki and its subsequent revisions (WMADH, 2008). Freely-given informed consent document was obtained from the legal guardian of each patient after ensuring that they have understood the purpose of the study. The genetic analyses were conducted in the Laboratory of Pharmacogenetics and Pharmacokinetics at the Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Bangladesh.

2.2. Genotyping

3 ml of venous blood was collected from all patients in sterile tubes containing EDTA-Na2 and stored at -80 °C until genomic DNA (gDNA) extraction. gDNA was isolated from blood by previously published method [20]. The quantity and purity of the isolated DNA were assessed by using a UV Spectrophotometer (UV Prove v2.1) at 260 nm. PCR-RFLP method was employed for genotyping the selected single nucleotide polymorphism (SNP). The relevant genomic target region, containing the SNP of interest, was amplified by means of primer-directed PCR using thermostable DNA polymerase and subsequently digested with specific restriction endonuclease, ClaI (NEB®, USA). Visualization of the digested PCR fragments was done by 2% agarose gel electrophoresis after staining with ethidium bromide. To avoid false positive genotype, 20% of the samples were sequenced. Moreover, exons 7 and 8 of R229Q heterozygous patients were PCR amplified from gDNA using predesigned primers and directly sequenced by capillary electrophoresis according to previously published methods [21, 22] with necessary optimization. All primer sequences can be found in the supplementary table 1.

2.3. Statistical analyses

Student t-test and chi-square (χ2) test were applied to compare the demographic data between SSNS and SRNS patients. Deviation of genotype frequencies in the control group from case group under Hardy–Weinberg equilibrium (HWE) was measured by chi-square test (χ2). A multivariate logistic regression analysis was performed to assess the odd ratios (ORs) and 95% confidence interval (95% CI) adjusted to age and sex. In all of the analyses, p < 0.05 was considered statistically significant. All statistical analyses were done applying the SPSS software, version 23.0.

3. Results

3.1. Characteristics of study population

The study included a total of 142 NS children with mean age of 4.9 years. Detailed demographics and clinicopathological features can be

### Table 1. Demographics and clinicopathological features of SRNS and SSNS children.

| Characteristics | SRNS (n = 40) | SSNS (n = 102) | p value |
|-----------------|--------------|---------------|---------|
| Male:Female     | 32:8         | 72:30         | -       |
| Age of onset (year) | 5.39 ± 1.42  | 4.79 ± 0.65   | 0.0007  |
| Weight (kg)     | 19.43 ± 2.57 | 18.25 ± 2.76  | 0.0209  |
| Height (cm)     | 117.5 ± 3.39 | 116.9 ± 4.66  | 0.4603  |
| Body surface area (m²) | 1.0 ± 0.01    | 0.99 ± 0.01   | 0.0001  |
| Systolic blood pressure (mm Hg) | 106.92 ± 2.62 | 105.71 ± 2.97 | 0.0257  |
| Diastolic blood pressure (mm Hg) | 78.09 ± 1.50  | 77.40 ± 0.97  | 0.0015  |
| Serum albumin (g/dL) | 1.98 ± 0.52   | 2.07 ± 0.37   | 0.2496  |
| Serum cholesterol (mg/dL) | 393.7 ± 155.37 | 347.2 ± 129.8 | 0.0718  |
| Serum creatinine (mg/dL) | 0.80 ± 0.04   | 0.78 ± 0.05   | 0.054   |
| Serum urea nitrogen (mg/dL) | 13.49 ± 2.54  | 12.50 ± 3.07  | 0.0725  |
| 24-hr urine protein (mg/L) | 384.1 ± 71.3  | 339.6 ± 44.2  | 0.0001  |
| Histopathological types (n) | 23 | 35 |
| FSGS            | 10           | 13            |         |
| MCNS            | 6            | 9             |         |
| MPGN            | 4            | 5             |         |
| Others          | 3            | 8             |         |

FSGS, Focal segmental glomerulosclerosis; MCNS, Minimal change glomerulonephritis; MPGN, Membranoproliferative glomerulonephritis. All data are presented as Mean ± SD. * Result is statistically significant (p < 0.05).
found in Table 1. Age of onset, weight, body surface area, blood pressure and 24-h urine protein level were found to be statistical different between SRNS and SSNS children groups. Focal segmental glomerulosclerosis (FSGS) was reported as the predominant (39.66%) histopathological finding from 58 available biopsy reports. All the children exhibited scanty micturition, puffed face and generalized edema. Around 85.92% children were diagnosed with NS at the age of 4–6 years. Besides, 62.5% SRNS represented early onset between the age 4–6 years. Age was found to be a statistically significant factor for SRNS (adjusted OR = 1.06; 95% CI = 1.023–1.094; p = 0.001) when compared to SSNS patients. Of 102 SSNS patients, 72 were male and 30 were female, whereas there were 32 males and 8 females in the SRNS patients. However, high prevalence of the male patients was not found to be a risk factor for SRNS in Bangladeshi children (adjusted OR = 1.67; 95% CI = 0.689–4.035; p = 0.257) (Table 2).

3.2. Correlation of R229Q polymorphism with SRNS

Figure 1 shows the DNA fragment pattern of ClaI digestion of the PCR products carried out to identify the variations at codon 229. Two bands at 184 bp and 361 bp demonstrated Arg/Arg homozygous genotype, three bands at 184 bp, 361 bp and 545 bp indicated Arg/Gln heterozygous genotype and one band at 545 bp represented Gln/Gln mutant homozygous genotype.

The genotypic frequencies of SSNS and SRNS patients are demonstrated in Table 3. The percent distribution of Arg/Arg homozygous genotype was significantly lower in SRNS patients than in SSNS patients (72.50% vs 87.25%). Significant relationship was found between the Arg/Gln heterozygous genotype and susceptibility to SRNS, with an adjusted OR of 2.94 (95% CI = 1.147–7.557; p < 0.05) when compared to Arg/Arg homozygous genotype. The Gln/Gln mutant homozygous genotype was not found in any of the study group (SRNS and SSNS). In addition, analysis of exons 7 and 8 of R229Q heterozygous children revealed the presence of trans-associated p.Ala297Val variant in exon 8.

4. Discussion

In the present study, we investigated whether there is any risk association between *NPHS2* gene R229Q polymorphic variant and SRNS susceptibility in Bangladeshi NS children. We also investigated the relation of this polymorphism with different demographic characteristics in NS children.

R229Q polymorphism is one of the most commonly found podocin sequence variations. The arginine residue at protein position 229 is highly conserved across species, which is substituted by glutamine in case of polymorphism. This results in consequent disruption of the functional properties of podocin in vitro and possibly in vivo [23]. R229Q variant is abundant in patients with SRNS which indicates that it has certain role in the SRNS disease state [13]. In our findings, SRNS children possess 2.94-fold increased risk of carrying the Arg/Gln heterozygous genotype compared to SSNS children which is consistent with several

![Figure 1.](image-url) Restriction Endonuclease (ClaI) digestion fragment of NPHS2 gene with R229Q polymorphism (2% agarose gel). NH: Normal homozygous (wild type) variant having two bands at 184 bp and 361 bp; HE: Heterozygous variant having three bands at 184 bp, 361 bp and 545 bp.

Table 3. Genotype frequencies of *NPHS2* gene R229Q polymorphism in nephrotic syndrome children.

| Genotypes | SRNS n = 40 (%) | SSNS n = 102 (%) | Adjusted Odds Ratio (AORs) | 95% CI       | p value |
|-----------|----------------|-----------------|---------------------------|--------------|---------|
| GG (Arg/Arg) | 29 (72.50) | 89 (87.25) | Ref. | - | - |
| GA (Arg/Gln) | 11 (27.50) | 13 (12.75) | 2.94 | 1.147–7.557 | 0.025 |
| AA (Gln/Gln) | 0 | 0 | 0 | 0 | 0 |

* Result is statistically significant (p < 0.05).
other case-control studies conducted in South Asian population [5, 24, 25]. On the contrary, a few studies conducted in SRNS patients found no correlation between this variant and NS [26, 27]. Moreover, a study conducted by Tory et al. [28] reported that the pathogenicity of R229Q variant of NPHS2 gene in SRNS is dependent on the trans-association of some specific mutations i.e. p.Ala284Val, p.Ala288Thr, p.Arg291Trp, p.Ala297Val, p.Glu310Lys, p.Glu310Val, p.Leu327Phe and p.Gln328Arg located in exons 7 and 8. This is due to the fact that R229Q variant protein coexpressed with any of these specific mutations shows altered dimerization resulting in the retention of R229Q variant protein within the cytoplasmic compartments. Therefore, further analysis into the exons 7 and 8 of our 11 SRNS and 13 SSNS children, we observed that all 11 SRNS children contain only p.Ala297Val mutation in exon 8 corroborating with the findings of Tory et al. [28]. Having such rarity of other above mentioned mutations might reflect a true finding or inadequate sample size, differences among ethnicities which is yet to be determined. Therefore, it is cautionary to analyze exon 8 along with R229Q heterozygosity in order to confirm its pathogenicity in Bangladeshi SRNS children.

The current study also investigated the genotype-phenotype correlations between R229Q polymorphism and age of onset. We reported all 11 heterozygous genotype carriers in SRNS children aged between 4-6 years but failed to correlate R229Q polymorphism with the risk of developing early-onset SRNS. This is in disagreement with Hinkes et al. who compared early-onset SRNS. This is in disagreement with Hinkes et al. and Boute et al. who conducted by Tory et al. [28] reported that the pathogenicity of R229Q variant of NPHS2 (podocin) gene in sporadic cases and Macuca et al. [13] identified NPHS2 substitutions in 14% of cases presenting with SRNS after 18 years of age. Furthermore, Santin et al. supported that late childhood and adult-onset SRNS had a similar NPHS2 p.R229Q detection rate than those with early childhood-onset [30].

In this study, statistically, we could not differentiate any gender-specific risk for developing steroid resistance (p value < 0.257) in NS patients. However, several studies reported contradiction to our finding. Ali et al. established male predominance with statistical significance in case of p.R229Q [31]. Similar findings were observed in studies of different region [32, 33, 34, 35]. In our study, the total SRNS ratio of male vs female is 80% vs 20% which indicates the much higher rate of male susceptibility towards the disease. Besides, the gender discrepancy was also observed in case of p.R229Q frequency distribution (male 80% vs female 20%). The statistical dissimilarity to the male susceptibility might be due to small sample size.

In conclusion, this is the first study to identify NPHS2 p.R229Q heterozygosity trans associated with specific mutation in exon 8 may cause pathogenic steroid resistance in Bangladeshi NS children. Future studies with a larger sample size in different ethnicities must be conducted to evaluate the statistical significance.

Declarations

Author contribution statement

S. Jyoti and F. Islam: Performed the experiments; Wrote the paper.
I. Shrabonee: Contributed reagents, materials, analysis tools or data.
T. Sultana and N. Chaitly: Performed the experiments.
N. Nahid, M.R. Islam and M.S. Islam: Conceived and designed the experiments; Analyzed and interpreted the data.
M. Apu: Conceived and designed the experiments; Analyzed and interpreted the data; Wrote the paper.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interest statement

The authors declare no conflict of interest.

Additional information

Supplementary content related to this article has been published online at https://doi.org/10.1016/j.heliyon.2020.e05317.

Acknowledgements

The authors are thankful to the patients, their families, volunteers, nurses, physicians, collaborators, and scientists of the Bangabandhu Sheikh Mujib Medical University (BSMMU) and Mymensingh Medical College Hospital (MMCH). The authors would also like to thank the Department of Clinical Pharmacy and Pharmacology, University of Dhaka, Bangladesh to provide lab facilities and other opportunities to carry out the research work.

References

[1] S.K.N. Mulukala, R. Nishad, L.P. Kolligundla, M.A. Saleem, N.P. Prabhu, A.K. Pasupuleti, In silico Structural characterization of podocin and assessment of nephrotic syndrome-associated podocin mutants, IUBMB Life 68 (2016) 578–588.
[2] Z. Yu, J. Ding, J. Huang, Y. Yao, H. Xiao, J. Zhang, J. Liu, J. Yang, Mutations in NPHS2 in sporadic steroid-resistant nephrotic syndrome in Chinese children, Nephrol. Dial. Transplant. 20 (2005) 902–908.
[3] M.S. Guaranga, A.C.G.B. Lataf, A.T. Maciel-Guerra, V.M.S. Belangero, G. Guerra-Júnior, M.P. De Mello, NPHS2 mutations: a closer look to Latin American countries, BioMed Res. Int. (2017).
[4] J.R. Saleedo, M.A. Thabet, K. Latta, J.C.M. Chan, Nephrosis in childhood, Nephron 71 (1995) 373–385.
[5] O.P. Mishra, N. Kakani, A.K. Singh, G. Narayanan, A. Abhinay, P. Prasad, V.V. Batra, NPHS2 R229Q polymorphism in steroid resistant nephrotic syndrome: is it responsive to immunosuppressive therapy? J. Trop. Pediatr. 60 (2014) 231–237.
[6] F. Wang, Y. Zhang, J. Mao, Z. Yu, Z. Li, L. Yu, J. Sun, X. Wei, F. Ding, H. Zhang, H. Xiao, Y. Yao, W. Tan, S. Lovric, J. Ding, F. Hildebrandt, Spectrum of mutations in Chinese children with steroid-resistant nephrotic syndrome, Pediatr. Nephrol. Berl. Ger. 32 (2017) 1181–1192.
[7] A.C. Pereira, A.B. Pereira, G.F. Mota, R.S. Cunha, F.L. Herkenhoff, M.R. Pollak, J.G. Mill, J.E. Krieger, P. Rieberger, NPHS2.R229Q functional variant is associated with microalbuminuria in the general population, Kidney Int. 65 (2004) 1026–1030.
[8] H. Mohey, L. Thibaudin, B. Laurent, F. Berthoux, The podocin mutation R229Q and early recurrence (within the first year) of glomerular disease after renal transplantation, Ann. Transplant. 18 (2013) 436–442.
[9] A.T. Jaffer, W.U. Ahmed, D.S. Raja, P. Jahan, Footprint of NPHS2 mutations in primary nephrotic syndrome, J. Postgrad. Med. 57 (2011) 314.
[10] N. Boute, O. Gribouval, S. Roxelli, F. Benessy, H. Lee, A. Fuchshuber, K. Dahan, M.C. Gubler, P. Niaudet, C. Antignac, NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome, Nat. Genet. 24 (2000) 349–354.
[11] M.P. Winn, No all in the family: mutations of podocin in sporadic steroid-resistant nephrotic syndrome, J. Am. Soc. Nephrol. JASN 13 (2002) 577–579.
[12] J.A.E. Dusel, K.P. Burdon, P.J. Hicks, G.A. Hawkins, D.W. Bowden, B.I. Freedman, Identification of podocin (NPHS2) gene mutations in African Americans with nonidiopathic end-stage renal disease, Kidney Int. 68 (2005) 256–262.
[13] E. Macuca, A. Hummel, F. Nevo, J. Dantát, F. Martínez, E. Al-Saliban, V. Baudouin, L. Abel, J.-P. Grinfeld, C. Antignac, Clinical and epidemiological assessment of steroid-resistant nephrotic syndrome associated with the NPHS2 R229Q variant, Kidney Int. 79 (2006) 727–735.
[14] L. Lu, H. Wen, Y. Yin, W.-J. Feng, M. Wang, Y.-C. Zou, B. Huang, D.-T. Wang, Y. Shi, Y. Zhao, L.-B. Wei, The p.R229Q variant of the NPHS2 (podocin) gene in focal segmental glomerulosclerosis and steroid-resistant nephrotic syndrome: a meta-analysis, Int. Urol. Nephrol. 46 (2014) 1383–1393.
[15] H. Tsukaguchi, A. Sudbakar, T.C. Le, T. Nguyen, J. Yao, J.A. Schwimmer, A.D. Schachter, E. Poch, P.F. Abreu, G.B. Appel, A.B. Pereira, R. Kalluri, M.R. Pollak, NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele, J. Clin. Invest. 110 (2002) 1659–1666.
Steroid responsive nephrotic syndrome is more common in Asians, Arch. Dis. Child. 60 (1985) 1014–1017.

T.L. Chambers, Forfar & arnoll’s textbook of pediatrics: 6th edition, J. R. Soc. Med. 97 (2004) 96.

P.M. Sharples, J. Poulton, R.H. White, Steroid responsive nephrotic syndrome is T.L. Chambers, Forfar

T.L. Chambers, Forfar

M.S. Bin Sayeed, M.N. Hasan Apu, M.T. Munir, M.U. Ahmed, M.S. Islam, T.J. Neuhaus, J. Fay, M.J. Dillon, R.S. Trompeter, T.M. Barratt, Alternative W.L. Robson, A.K. Leung, Nephrotic syndrome in childhood, Adv. Pediatr. 40 (1993) 287–323.

T.J. Neuhaus, J. Fay, M.J. Dillon, R.S. Trompeter, T.M. Barratt, Alternative P. Jahan, A. Jaffer, W. Unnisa, U. Mahwish, G. Latha, S. Sagurthi, D. Raju, NPHS2

L.M. McKenzie, S.L. Hendrickson, W.A. Briggs, R.A. Dart, S.M. Korbet, M.H. Mekrziyki, P.L. Kimmel, T.S. Ahuja, J.S. Berns, E.E. Simon, M.C. Smith, H. Trachtman, D.M. Michel, J.R. Schelling, M. Cho, Y.C. Zhou, E. Binns-Roemer, G.D. Kirk, J.B. Kopp, C.A. Winkler, NPHS2 variation in sporadic focal segmental glomerulosclerosis, J. Am. Soc. Nephrol. JASN 18 (2007) 2997–2995.

J. Reiterová, H. Safráznková, L. Obiedová, J. Stekrová, D. Maišnerová, M. Merta, V. Tesar, Mutational analysis of the NPHS2 gene in Czech patients with idiopathic nephrotic syndrome, Folia Biol. (Praha). 58 (2012) 64–68.

K. Tory, D.K. Menyhard, S. Woerner, F. Nevo, O. Gribouval, A. Kerti, P. Sträuner, C. Arrondel, E. Huyyn Cong, T. Tulasney, G. Mollet, A. Perczel, C. Antignac, Mutation-dependent recessive inheritance of NPHS2-associated steroid-resistant nephrotic syndrome, Nat. Genet. 46 (2014) 299–304.

B.G. Hinkes, B. Mucha, C.N. Wangoo, R. Ghadegenin, J. Liu, K. Hasselbacher, D. Hangan, F. Ozaltin, M. Zenker, F. Hildebrandt, Arbeitsgemeinschaft für Paediatrische Nephrologie Study Group, Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2), Pediatrics 119 (2007) e907–e919.

S. Santín, G. Bullich, B. Tazón-Vega, R. García-Manet, I. Giménez, I. Silva, P. Ruiz, J. Ballarín, R. Torra, E. Aró, Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome, Clin. J. Am. Soc. Nephrol. CJASN 6 (2011) 1139–1148.

S.H. Ali, R.K. Mohammed, H.A. Saheb, B.A. Abdullahjeed, R229Q polymorphism of NPHS2 gene in group of Iraqi children with steroid-resistant nephrotic syndrome, Int. J. Nephrol. 2017 (2017).

A. Berdeli, S. Mir, O. Yavascan, E. Serdaroglu, M. Bak, N. Aksoy, A. Onar, O. Donmez, N. Yildiz, L. Sever, Y. Tabel, R. Dausumel, F. Sonmez, N. Cakar, NPHS2 (podocin) mutations in Turkish children with idiopathic nephrotic syndrome, Pediatr. Nephrol. Berl. Ger. 22 (2007) 2031–2040.

R. Ghadegenin, B. Barkowski, P.J. Lavin, N. Mukerji, G. Wu, B. Bowling, J. Eckel, T. Damodaran, M.P. Winn, Exclusion of homozygous PLCE1 (NPHS3) mutations in 69 families with idiopathic and hereditary FSGS, Pediatr. Nephrol. Berl. Ger. 24 (2009) 281–285.

G. Chemin, S.P. Heerenga, V. Vega-Warner, D.S. Schoeber, O. F. Hildebrandt, Adequate use of allele frequencies in Hispanics—a problem elucidated in nephrotic syndrome, Pediatr. Nephrol. Berl. Ger. 25 (2010) 261–266.

D. Feng, Y.H. Yang, D. Wang, D. Meng, R. Fu, J. Wang, Z. Yu, Mutational analysis of podocyte genes in children with sporadic steroid-resistant nephrotic syndrome, Genet. Mol. Res. GMR 13 (2014) 9514–9522.